Thomas Kassberg
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Thomas Kassberg
The proxy statement of Ultragenyx Pharmaceutical Inc. reports total compensation of $2,456,501 for Thomas Kassberg in fiscal 2019, including a base salary of $474,000. Disclosed compensation is on record for 3 fiscal years.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Ultragenyx Pharmaceutical Inc. (RARE)
Proxy statement
Start not stated–2025-03-28
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2019 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Business Officer and Executive Vice President | $474,000 | $2,456,501 |
| 2018 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Business Officer and Executive Vice President | $441,340 | $1,692,660 |
| 2017 | Ultragenyx Pharmaceutical Inc. (RARE) | Chief Business Officer and Executive Vice President | $418,443 | $2,331,661 |
Recent activity
No call appearances or filed executive changes recorded yet.